Walnut: The Effects of the Food Preservative Propionic Acid in Post-prandial Metabolism

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01889446
Collaborator
(none)
20
1
2
22
0.9

Study Details

Study Description

Brief Summary

Propionic acid (PA) is used as a preservative in foods such as cheeses, baked goods, or additive for artificial fruit flavors. The U.S. Environmental Protection Agency considers it safe and therefore, has no limitation on its use. Since PA has been shown before to serve as a substrate for glucose production in the liver, the purpose of this study is to find out if PA intake causes changes in levels of glucose, insulin and other important hormones following a meal.

This research study will compare PA to placebo. The placebo looks exactly like the active substance, but it does not contain any active agent (PA). Placebos are used in research studies to see if the results are due to the study drug or to other reasons.

The investigators plan to have 20 subjects take part in this study at the Brigham and Women's Hospital (BWH).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Calcium propionate
N/A

Detailed Description

-To test whether PA, added as food supplement to humans, results in altered post-prandial metabolism. The investigators propose to conduct a double-blind, randomized, placebo controlled, cross-over study in which blood levels of metabolites and hormones will be measured in healthy volunteers following a mixed meal test without or with PA.

Study design:

This is a double-blind, randomized, placebo controlled, cross-over study. Twenty volunteers who meet the inclusion/exclusion criteria will be randomized into two groups, provided with a mixed meal without or with calcium proprionate (also known as E282). A week later, participants will be provided with a mixed meal again, following cross-over of the groups. Blood will be collected at baseline, and every 30 minutes for 4 hours.

Study Subjects:

20 healthy male and female volunteers (ages 18 to 65 years) with a body mass index (BMI) of 20 to <30 Kg/m2.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Basic Science
Official Title:
Pilot Study to Study the Effects of the Food Preservative Calcium Propionate on Postprandial Hormonal and Metabolic Milieu
Study Start Date :
Aug 1, 2013
Anticipated Primary Completion Date :
Jun 1, 2015
Anticipated Study Completion Date :
Jun 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Calcium propionate

Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.

Dietary Supplement: Calcium propionate

Placebo Comparator: Placebo

Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.

Outcome Measures

Primary Outcome Measures

  1. Post prandial insulin levels [During 4 hours after consumption of a meal]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18-65 years

  • Good health as evidenced by history and physical exam

  • BMI: 20-29.9 kg/m2

Exclusion Criteria:
  • Fasting plasma glucose >110 mg/dL

  • HbA1c >6.0%

  • Significant current illness other than treated hypothyroidism

  • BP >135/85 or systolic BP <90 mm Hg

  • Hepatic disease (transaminase > 3 times normal)

  • Renal impairment (Creatinine clearance <60 ml/min)

  • History of drug or alcohol abuse

  • Participation in any other concurrent clinical trial

  • Pregnant women

  • History of food allergies.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brigham and Women's Hospital Boston Massachusetts United States 02115

Sponsors and Collaborators

  • Brigham and Women's Hospital

Investigators

  • Principal Investigator: Amir Tirosh, MD PhD, Brigham and Women's Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amir Tirosh, MD,PhD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01889446
Other Study ID Numbers:
  • 2013P001197
First Posted:
Jun 28, 2013
Last Update Posted:
Sep 22, 2014
Last Verified:
Sep 1, 2014
Keywords provided by Amir Tirosh, MD,PhD, Brigham and Women's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2014